PASADENA, Calif.--(BUSINESS WIRE)--Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted an “orphan drug” designation to Genervon’s GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a “fast-track” designation for ALS in 2013.
Help employers find you! Check out all the jobs and post your resume.
